Histology
Non-Small Cell Carcinoma
CI-CAN-00001292Explore in graph →
1,752 active trials47 approved drugs589 evidence items
- NCIt
- C65151
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001292Explore in graph →
Clinical trials
6,757 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,046)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02574078 | A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)(CheckMate370) | completed | Phase 1 / Phase 2 | 341 | Bristol-Myers SquibbINDUSTRY | 1 | May 6, 2021 | clinicaltrials |
| NCT03394118 | TAGRISSO (Osimertinib) in NSCLC Patients in Whom T790 Mutations Are Detected by Liquid Biopsy | completed | Phase 2 | 63 | Asan Medical CenterOTHER | 1 | Apr 27, 2021 | clinicaltrials |
| NCT01610336 | A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment | completed | Phase 2 | 161 | Novartis PharmaceuticalsINDUSTRY | 14 | Apr 8, 2021 | clinicaltrials |
| NCT03595644 | Maintenance Targeted Therapy With or Without Stereotactic Body Radiation Therapy for Stage IV Non-small Cell Lung Cancer | completed | Phase 2 | 74 | Tongji HospitalOTHER | 1 | Apr 8, 2021 | clinicaltrials |
| NCT01577654 | Phase 2 Study of EC145 Alone Versus EC145+Docetaxel Versus Docetaxel Alone in Participants With FR(++) 2nd Line Non Small Cell Lung Cancer(TARGET) | completed | Phase 2 | 203 | EndocyteINDUSTRY | 0 | Apr 1, 2021 | clinicaltrials |
| NCT02450903 | LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib. | completed | Phase 2 | 20 | Novartis PharmaceuticalsINDUSTRY | 1 | Mar 30, 2021 | clinicaltrials |
| NCT01967823 | T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer | completed | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | Mar 24, 2021 | clinicaltrials |
| NCT02085070 | MK-3475 in Melanoma and NSCLC Patients With Brain Metastases | completed | Phase 2 | 65 | Yale UniversityOTHER | 1 | Mar 24, 2021 | clinicaltrials |
| NCT01066234 | Adjuvant CCRT vs CT in Minimal N2 NSCLC | completed | Phase 2 | 17 | Samsung Medical CenterOTHER | 1 | Mar 22, 2021 | clinicaltrials |
| NCT02747953 | Gilotrif (Afatinib) in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib | completed | Phase 2 | 50 | Samsung Medical CenterOTHER | 0 | Mar 19, 2021 | clinicaltrials |
| NCT02094573 | A Study to Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib | completed | Phase 2 | 222 | Ariad PharmaceuticalsINDUSTRY | 0 | Mar 15, 2021 | clinicaltrials |
| NCT03736837 | Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC(ALTER-L004) | completed | Phase 2 | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Mar 15, 2021 | clinicaltrials |
| NCT00606502 | Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment | completed | Phase 2 | 201 | Spectrum Pharmaceuticals, IncINDUSTRY | 6 | Mar 5, 2021 | clinicaltrials |
| NCT01820754 | Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC)(TOP1201 IPI) | completed | Phase 2 | 24 | Duke UniversityOTHER | 1 | Feb 26, 2021 | clinicaltrials |
| NCT03157089 | Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung(LUX-Lung-IO) | completed | Phase 2 | 24 | Boehringer IngelheimINDUSTRY | 5 | Feb 23, 2021 | clinicaltrials |
| NCT00219297 | Study of Patupilone in Patients With Brain Metastasis From Non-small Cell Lung Cancer | completed | Phase 2 | 50 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 21, 2021 | clinicaltrials |
| NCT01327612 | Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) | completed | Phase 2 | 12 | AmgenINDUSTRY | 3 | Feb 21, 2021 | clinicaltrials |
| NCT01945021 | Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC | completed | Phase 2 | 129 | PfizerINDUSTRY | 4 | Feb 21, 2021 | clinicaltrials |
| NCT01102231 | Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 106 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Feb 16, 2021 | clinicaltrials |
| NCT02577341 | Nimotuzumab Combined With Chemoradiotherapy for Unresectable Locally Advanced Squamous Cell Lung Cancer | completed | Phase 2 | 122 | Sun Yat-sen UniversityOTHER | 1 | Feb 11, 2021 | clinicaltrials |
| NCT01635270 | Phase 2 Study Evaluating Mid-position Strategy in Radiotherapy Treatment for Patients With a Locally Advanced Non-small Cell Lung Carcinoma(midP) | completed | Phase 2 | 54 | Centre Leon BerardOTHER | 1 | Feb 5, 2021 | clinicaltrials |
| NCT03044626 | Fostering Efficacy of Anti - PD-1 - Treatment: Nivolumab Plus Radiotherapy in Advanced NSCLC(FORCE) | completed | Phase 2 | 101 | AIO-Studien-gGmbHOTHER | 1 | Jan 13, 2021 | clinicaltrials |
| NCT01573702 | Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR) | completed | Phase 2 | 32 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jan 12, 2021 | clinicaltrials |
| NCT02574598 | MK-3475 in Combination With Docetaxel vs Docetaxel Alone in Non-Small Cell Lung Cancer Patients | completed | Phase 2 | 78 | Instituto Nacional de Cancerologia de MexicoOTHER | 1 | Jan 6, 2021 | clinicaltrials |
| NCT02082210 | A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer | completed | Phase 1 / Phase 2 | 97 | Eli Lilly and CompanyINDUSTRY | 1 | Dec 19, 2020 | clinicaltrials |
| NCT02308020 | A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain | completed | Phase 2 | 162 | Eli Lilly and CompanyINDUSTRY | 9 | Dec 19, 2020 | clinicaltrials |
| NCT02276027 | A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer | completed | Phase 2 | 66 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 16, 2020 | clinicaltrials |
| NCT01823068 | Vandetanib in Advanced NSCLC With RET Rearrangement | completed | Phase 2 | 17 | Samsung Medical CenterOTHER | 1 | Dec 7, 2020 | clinicaltrials |
| NCT00888511 | Tarceva And Radiotherapy in Locally Advanced Lung Cancer Non-small Cell Lung Cancer(TARLAL) | completed | Phase 2 | 15 | Olfred HansenOTHER | 1 | Nov 27, 2020 | clinicaltrials |
| NCT02730247 | Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 7 | Liza Villaruz, MDOTHER | 1 | Nov 19, 2020 | clinicaltrials |
| NCT00415363 | Study of Enzastaurin Versus Placebo in the Treatment of Patients With Brain Metastases of Lung Cancer, After Whole Brain Radiation Therapy | completed | Phase 2 | 109 | Eli Lilly and CompanyINDUSTRY | 5 | Nov 5, 2020 | clinicaltrials |
| NCT00723957 | A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Advanced Nonsmall-Cell Lung Cancer | completed | Phase 2 | 260 | R-PharmINDUSTRY | 10 | Oct 28, 2020 | clinicaltrials |
| NCT02785913 | Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches | completed | Phase 2 | 31 | SWOG Cancer Research NetworkNETWORK | 2 | Oct 23, 2020 | clinicaltrials |
| NCT00553254 | Trial Of PF-00299804 In Patients With Advanced Refractory Lung Cancer | completed | Phase 2 | 55 | PfizerINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT01702844 | Single Arm on the Tolerability of Weekly Nab-paclitaxel | completed | Phase 2 | 42 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Oct 8, 2020 | clinicaltrials |
| NCT01532089 | Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations | completed | Phase 2 | 88 | Academic and Community Cancer Research UnitedOTHER | 1 | Oct 6, 2020 | clinicaltrials |
| NCT02879760 | Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer Patients | completed | Phase 1 / Phase 2 | 16 | Turnstone Biologics, Corp.INDUSTRY | 1 | Oct 6, 2020 | clinicaltrials |
| NCT00835471 | 2nd Line Erlotinib Treatment With (Out) Chemotherapy of Advanced Non Small Cell Lung Cancer (NSCLC)(NVALT10) | completed | Phase 2 | 195 | Dutch Society of Physicians for Pulmonology and TuberculosisOTHER | 1 | Sep 29, 2020 | clinicaltrials |
| NCT01171170 | Paclitaxel-Carboplatin-Bevacizumab +/- Nitroglycerin in Metastatic Non-Squamous-Non-Small Cell Lung Cancer(NVALT12) | completed | Phase 2 | 223 | Dutch Society of Physicians for Pulmonology and TuberculosisOTHER | 1 | Sep 28, 2020 | clinicaltrials |
| NCT00950365 | Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer | completed | Phase 2 | 79 | Albert Einstein College of MedicineOTHER | 1 | Sep 16, 2020 | clinicaltrials |
| NCT03450330 | Assessing an Oral Janus Kinase Inhibitor, AZD4205, in Combination With Osimertinib in Patients Who Have Advanced Non-small Cell Lung Cancer(JACKPOT1) | completed | Phase 1 / Phase 2 | 10 | Dizal PharmaceuticalsINDUSTRY | 1 | Aug 24, 2020 | clinicaltrials |
| NCT01218516 | A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung | completed | Phase 2 | 130 | MorphotekINDUSTRY | 8 | Aug 20, 2020 | clinicaltrials |
| NCT03086733 | Phase II Lung Metcore - Preoperative Metformin for Lung Cancer(Metcore) | completed | Phase 2 | 28 | University Health Network, TorontoOTHER | 1 | Aug 19, 2020 | clinicaltrials |
| NCT02492568 | Pembrolizumab After SBRT Versus Pembrolizumab Alone in Advanced NSCLC(PEMBRO-RT) | completed | Phase 2 | 92 | The Netherlands Cancer InstituteOTHER | 1 | Aug 17, 2020 | clinicaltrials |
| NCT01833143 | Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D | completed | Phase 2 | 17 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 4, 2020 | clinicaltrials |
| NCT02490696 | Comparative Study of the Hypoxia Measured in FAZA and F-miso PET/CT Scan in Patients With Non-small Cell Lung Cancer(RTEP6) | completed | Phase 2 | 23 | Centre Henri BecquerelOTHER | 1 | Jul 30, 2020 | clinicaltrials |
| NCT00866970 | Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue and Cachexia | completed | Phase 2 | 124 | CSL BehringINDUSTRY | 9 | Jul 9, 2020 | clinicaltrials |
| NCT00530621 | Study of Enzastaurin Versus Placebo With Pemetrexed for Participants With Advanced or Metastatic Lung Cancer | completed | Phase 2 | 160 | Eli Lilly and CompanyINDUSTRY | 6 | Jul 1, 2020 | clinicaltrials |
| NCT01941654 | ATOM_local Ablative Therapy | completed | Phase 2 | 18 | Chinese University of Hong KongOTHER | 1 | Jun 18, 2020 | clinicaltrials |
| NCT01101334 | Study of Erlotinib With or Without Investigational Drug (CS-7017) in Subjects With Advanced Non-small Cell Lung Cancer | completed | Phase 2 | 90 | Daiichi SankyoINDUSTRY | 4 | Jun 16, 2020 | clinicaltrials |
Data updated 23 days agoSource updated May 6, 2021source: clinicaltrials